BACKGROUND: Bicuspid aortic valve (BAV) aortopathy is well known in literature even if only few data exist regarding isolated supra-coronary aneurysm with normally functioning valve and root. Aim of this study is to clarify the long-term fate of bicuspid aortic root spared at the time of ascending aorta surgery. METHODS: We identified forty-seven patients (mean age, 57±11 y; range, 35-81 y, 31 males) who were treated by means of supracoronary aortic replacement in presence of normally functioning BAV and not significantly enlarged sinues of Valsalva. Clinical follow-up (mean 93±50 months; range, 21-207) was 98.9% complete. RESULTS: Freedom from cardiac death at 5- and 10-year was 95%±5% and 83%±16%. Three surviving patients required reoperation for the development of aortic insufficiency [2 cases treated by aortic valve replacement (AVR)] or for progression of aortic stenosis (AS) [1 case treated by transcatheter aortic valve implantation (TAVI)]. Freedom from new procedure on aortic valve was 100% and 94.4%±5.6% at 5- and 10-year. Composite event-free survival at 5- and 9-year was 82%±18% and 69%±30%. CONCLUSIONS: Although in the setting of a BAV, aortic root integrity seems to remain stable during long term follow up with low rate of reoperation and occurrence of new adverse event.
BACKGROUND:Bicuspid aortic valve (BAV) aortopathy is well known in literature even if only few data exist regarding isolated supra-coronary aneurysm with normally functioning valve and root. Aim of this study is to clarify the long-term fate of bicuspid aortic root spared at the time of ascending aorta surgery. METHODS: We identified forty-seven patients (mean age, 57±11 y; range, 35-81 y, 31 males) who were treated by means of supracoronary aortic replacement in presence of normally functioning BAV and not significantly enlarged sinues of Valsalva. Clinical follow-up (mean 93±50 months; range, 21-207) was 98.9% complete. RESULTS: Freedom from cardiac death at 5- and 10-year was 95%±5% and 83%±16%. Three surviving patients required reoperation for the development of aortic insufficiency [2 cases treated by aortic valve replacement (AVR)] or for progression of aortic stenosis (AS) [1 case treated by transcatheter aortic valve implantation (TAVI)]. Freedom from new procedure on aortic valve was 100% and 94.4%±5.6% at 5- and 10-year. Composite event-free survival at 5- and 9-year was 82%±18% and 69%±30%. CONCLUSIONS: Although in the setting of a BAV, aortic root integrity seems to remain stable during long term follow up with low rate of reoperation and occurrence of new adverse event.
Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Iung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Paolo Nardi; Antonio Pellegrino; Marco Russo; Guglielmo Saitto; Fabio Bertoldo; Luigi Chiariello Journal: Ann Thorac Surg Date: 2013-08-27 Impact factor: 4.330
Authors: Hector I Michelena; Valerie A Desjardins; Jean-François Avierinos; Antonio Russo; Vuyisile T Nkomo; Thoralf M Sundt; Patricia A Pellikka; A Jamil Tajik; Maurice Enriquez-Sarano Journal: Circulation Date: 2008-05-27 Impact factor: 29.690
Authors: Gruschen R Veldtman; Heidi M Connolly; Thomas A Orszulak; Joseph A Dearani; Hartzell V Schaff Journal: Mayo Clin Proc Date: 2006-03 Impact factor: 7.616
Authors: Alessandro Della Corte; Simon C Body; Anna M Booher; Hans-Joachim Schaefers; Rita K Milewski; Hector I Michelena; Arturo Evangelista; Philippe Pibarot; Patrick Mathieu; Giuseppe Limongelli; Prem S Shekar; Sary F Aranki; Andrea Ballotta; Giuseppe Di Benedetto; Natzi Sakalihasan; Gianantonio Nappi; Kim A Eagle; Joseph E Bavaria; Alessandro Frigiola; Thoralf M Sundt Journal: J Thorac Cardiovasc Surg Date: 2014-01-21 Impact factor: 5.209